Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159257 | 1.00 | HTR2B (0.47) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL4153583 | 0.82 | HTR2B (0.46) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL4153580 | 0.82 | HTR2B (0.46) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL22147102 | 0.80 | MAOB (0.44) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL21859244 | 0.80 | HTR2B (0.76) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL22073557 | 0.80 | HTR2B (0.76) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL21859242 | 0.80 | LMNA (0.76) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL4068688 | 0.78 | SRD5A1 (0.55) | HTR2BLMNASLC6A2ADRB2CHRM2 | |
| SCHEMBL4036590 | 0.77 | HTT (0.44) | HTR2BCYP3A4LMNASLC6A2CYP1A2 | |
| SCHEMBL4161951 | 0.77 | HTT (0.44) | HTR2BCYP3A4LMNASLC6A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | HTR2B 962/4885CYP3A4 385/4885LMNA 2774/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | HTR2B 891/4885CYP3A4 381/4885LMNA 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.